Data follows recent inclusion of
Adagrasib in NCCN Guidelines for PDAC and CNS Cancers
Additional Company Presentations Highlight
Real-World Observations in Patients Living with Metastatic NSCLC
and KRASG12C Mutated NSCLC
SAN
DIEGO, May 30, 2023 /PRNewswire/ -- Mirati
Therapeutics, Inc.® (NASDAQ: MRTX), a commercial
stage biotechnology company, today announced presentations and
posters to be shared at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting demonstrating the utility of
adagrasib across multiple tumor types.
The company will present encore data indicating
adagrasib, a potent and selective KRASG12C
inhibitor, is well tolerated and demonstrates meaningful clinical
activity in patients with previously treated pancreatic ductal
adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid
tumors harboring a KRASG12C mutation. Phase 2 data from
the KRYSTAL-1 study demonstrates the potential value of
adagrasib monotherapy for patients with unresectable or
metastatic KRASG12C-mutated solid tumors beyond
non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Data was previously shared at the April ASCO Plenary Series and
published in the Journal of Clinical Oncology as a Rapid
Communication, reserved for publications deemed to provide timely
and late breaking research that may have an immediate impact on
patient care.
This encore presentation follows the recent inclusion of
adagrasib in the National Comprehensive Center Network
(NCCN) Guidelines for both PDAC and Central Nervous System (CNS)
Cancers for patients living with previously treated
KRASG12C-mutant PDAC and non-small cell lung cancer
(NSCLC) with CNS metastases, respectively.
In addition, the company announced that it will present two
posters which highlight real-world observations in patients living
with metastatic NSCLC (mNSCLC). Full presentation details of all
three presentations are below:
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in
Patients with Advanced Solid Tumors Harboring a KRASG12C Mutation:
Saturday, June 3, 2023 at
10:30-11:45 p.m. PT / 12:30-1:45 PM CT (Abstract #425082) during the
ASCO Plenary Series: Rapid Abstract Updates Education Session. Full
abstract can be found here.
- Real-world study of treatment patterns and clinical outcomes in
patients with mNSCLC post-approval of immunotherapy in the
community oncology setting: Saturday,
June 3, 2023 at 11:15 a.m. –
2:15 p.m. PT / 2:15-5:15 p.m. ET (Abstract 6629) during the
Developmental Therapeutics – Molecularly Targeted Agents and Tumor
Biology Poster Session. Full abstract can be found here.
- Real-world outcomes of the first-line immune checkpoint
inhibitors with or without chemotherapy in KRAS G12C altered
NSCLC according to PD-L1 status: Sunday,
June 4, 2023 at 6:00 a.m. PT /
9:00 a.m. ET – 12:00 p.m. (Abstract 9136) during the Lung Cancer
– Non-Small Cell Metastatic Poster Session. Full abstract can be
found here.
"We're pleased to be back at the 2023 ASCO Annual Meeting to
share meaningful clinical results demonstrating the efficacy of
adagrasib in a range of tumor types beyond NSCLC and
CRC, indicating a potential path to regulatory approval for
adagrasib in additional indications," shared Alan Sandler, M.D., chief medical officer,
Mirati Therapeutics, Inc. "We are also eager to share the results
of our real-world studies to demonstrate the continued unmet need
within first-line NSCLC which continues to be an area of active
study for adagrasib in combination with pembrolizumab with
and without chemotherapy."
About Mirati Therapeutics, Inc.®
Mirati
Therapeutics, Inc. is a commercial stage biotechnology company
whose mission is to discover, design and deliver breakthrough
therapies to transform the lives of patients with cancer and their
loved ones. The company is relentlessly focused on bringing forward
therapies that address areas of high unmet need, including lung
cancer, and advancing a pipeline of novel therapeutics targeting
the genetic and immunological drivers of cancer. Unified for
patients, Mirati's vision is to unlock the science behind the
promise of a life beyond cancer.
For more information about Mirati, visit us
at Mirati.com or follow us
on Twitter, LinkedIn and Facebook.
Forward Looking Statements
This press release includes
forward-looking statements regarding Mirati's business, financial
guidance and the therapeutic and commercial potential of
KRAZATI® (adagrasib), MRTX1719 (MTA-cooperative PRMT5
inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective
KRASG12D inhibitor), Mirati's technologies and Mirati's other
products in development. Any statement describing Mirati's goals,
expectations, intentions or beliefs, financial or other
projections, is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, including those related to the
impact COVID-19 could have on our business, and including those
inherent in the process of discovering, developing and
commercializing medicines that are safe and effective for use as
human therapeutics, and in the endeavor of building a business
around such medicines.
Mirati's forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Mirati's forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Mirati. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning
Mirati's programs are described in additional detail in Mirati's
annual report on Form 10-K, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission and available at
the SEC's Internet site (www.sec.gov). These forward-looking
statements are made as of the date of this press release, and
Mirati assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
Mirati Contacts
Investor Relations:
ir@mirati.com
Media Relations: media@mirati.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirati-to-encore-compelling-clinical-data-demonstrating-adagrasibs-potential-as-a-targeted-treatment-for-krasg12c-mutated-advanced-solid-tumors-at-2023-asco-annual-meeting-301837683.html
SOURCE Mirati Therapeutics, Inc.